Skip to main content
. 2013 Dec 5;137(2):420–432. doi: 10.1093/brain/awt327

Figure 6.

Figure 6

ERBB2 expression is upregulated in sural nerve biopsies of patients with NF2. (A) Representative examples of immunohistochemical stainings for ERBB2 on mouse sciatic nerves deficient of merlin isoform 1 (nf2 iso1 KO) and wild-type controls. Visualization of bound antibodies with diaminobenzidine (brown), counterstained with Mayer’s haemalum. Scale bar = 20 µm. (B) Related quantifications to (A) of ERBB2-positive fibres in wild-type mice and merlin isoform1 knockout animals (data represent mean ± SEM; *P < 0.05; n = 3). (C) Immunoblot of sciatic nerve lysates showing that the loss of both major merlin isoforms in vivo is accompanied by increased ERBB2 levels (n = 2). Blot quantifications (density values) are depicted below respective lanes and are normalized to actin and wild-type samples. (D) Representative examples of immunohistochemical labelling of human sural nerve biopsies for ERBB2. Visualization of bound antibodies with diaminobenzidine (brown), counterstained with Mayer’s haemalum. Scale bar = 20 µm. (E) Quantifications of ERBB2-positive fibres in biopsies of controls as well as patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP), axonopathy, NF2 and vasculitis (data represent mean ± SEM; *P < 0.05; n = 3).